| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13% | $17,200,927 | 36,597,716 | Robert Nelsen | 31 Dec 2024 | |||
| Foresite Capital Fund IV, L.P. | 9.2% | +36% | $12,766,089 | +$3,611,010 | 27,161,892 | +39% | James B. Tananbaum | 31 Mar 2025 |
| BlackRock, Inc. | 4.5% | $6,234,958 | 13,265,869 | BlackRock, Inc. | 31 Dec 2024 | |||
| Explore Investments LLC/DE | 5.4% | $9,202,122 | 1,040,964 | Explore Investments LLC | 25 Jul 2025 |
As of 30 Sep 2025, 2 institutional investors reported holding 650,353 shares of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL). This represents 3.4% of the company’s total 19,277,111 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 650,353 | $10,561,733 | -$15,728,473 | $16.24 | 2 |
| 2025 Q2 | 2,440,673 | $21,579,143 | -$465,374,774 | $8.84 | 6 |
| 2025 Q1 | 152,354,676 | $81,758,597 | +$815,972 | $0.54 | 111 |
| 2024 Q4 | 150,286,895 | $95,884,372 | +$14,590,328 | $0.64 | 101 |
| 2024 Q3 | 128,413,620 | $176,562,559 | -$7,293,208 | $1.38 | 115 |
| 2024 Q2 | 133,365,913 | $193,952,761 | -$1,433,462 | $1.45 | 114 |
| 2024 Q1 | 132,843,101 | $296,874,901 | +$3,769,415 | $2.23 | 124 |
| 2023 Q4 | 131,309,565 | $255,237,592 | +$1,520,026 | $1.94 | 116 |
| 2023 Q3 | 122,510,290 | $180,096,177 | +$237,767 | $1.47 | 102 |
| 2023 Q2 | 122,233,983 | $388,698,764 | +$15,244,327 | $3.18 | 98 |
| 2023 Q1 | 117,770,423 | $277,898,040 | +$604,828 | $2.36 | 97 |
| 2022 Q4 | 116,732,928 | $404,998,862 | +$13,810,466 | $3.47 | 94 |
| 2022 Q3 | 112,406,834 | $823,966,061 | +$50,675,691 | $7.33 | 88 |
| 2022 Q2 | 105,615,240 | $688,647,561 | +$42,215,226 | $6.52 | 72 |
| 2022 Q1 | 99,521,989 | $502,714,970 | +$55,442,935 | $5.05 | 78 |
| 2021 Q4 | 85,540,866 | $662,180,000 | -$22,122,993 | $7.74 | 76 |
| 2021 Q3 | 82,534,412 | $1,221,509,324 | +$39,832,274 | $14.80 | 61 |
| 2021 Q2 | 79,701,853 | $1,294,200,800 | +$1,294,200,800 | $16.24 | 52 |